Literature DB >> 1357974

Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.

C L Collins1, N G Ordonez, R Schaefer, C D Cook, S S Xie, J Granger, P L Hsu, L Fink, S M Hsu.   

Abstract

Thrombomodulin (TM) is a glycoprotein of molecular weight 75,000 kd that is normally present in restricted numbers of cells, including endothelial and mesothelial cells. In this study, the authors tested the possibility of using anti-TM to facilitate the diagnosis of mesothelioma. All of the 31 mesotheliomas and the two mesothelioma cell lines (MS-1 and MS-2) tested were stained positively with anti-TM. The specificity of anti-TM staining in mesothelioma cells was further confirmed by in situ hybridization of MS-1 cells with a TM-specific probe. The expression of TM in MS-1 cells was increased markedly when these cells were induced by 12-0-tetradecanyl phorbol 13-acetate (TPA) to differentiate. The expression of TM in mesothelioma cells, however, did not correlate with any particular phase of the cell cycle. In an attempt to differentiate pleural mesothelioma from pulmonary adenocarcinoma, the authors compared the expression of TM, carcinoembryonic antigen (CEA), and Leu M1 in these two types of tumors. Only four of 48 (8%) pulmonary adenocarcinomas were stained positively by antibodies to TM. Therefore, immunohistochemical staining with antibodies to TM yielded 100% sensitivity and 92% specificity for diagnosis of mesothelioma. All of the mesotheliomas stained negatively for CEA and Leu M1, except for one, which showed minimal focal positivity for Leu M1. In contrast, 79% and 60% of adenocarcinomas stained positively for CEA and Leu M1, respectively. These findings suggest that immunocytochemical staining with anti-TM should be added to the battery of tests to increase the diagnostic sensitivity and specificity for differentiating mesothelioma from pulmonary adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357974      PMCID: PMC1886631     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  15 in total

1.  Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene.

Authors:  D Z Wen; W A Dittman; R D Ye; L L Deaven; P W Majerus; J E Sadler
Journal:  Biochemistry       Date:  1987-07-14       Impact factor: 3.162

2.  Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases.

Authors:  M R Wick; T Loy; S E Mills; J F Legier; J C Manivel
Journal:  Hum Pathol       Date:  1990-07       Impact factor: 3.466

3.  Thrombomodulin as a marker for vascular tumors. Comparative study with factor VIII and Ulex europaeus I lectin.

Authors:  S Yonezawa; I Maruyama; K Sakae; A Igata; P W Majerus; E Sato
Journal:  Am J Clin Pathol       Date:  1987-10       Impact factor: 2.493

4.  Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C.

Authors:  N L Esmon; W G Owen; C T Esmon
Journal:  J Biol Chem       Date:  1982-01-25       Impact factor: 5.157

5.  Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms.

Authors:  P T Cagle; L D Truong; V L Roggli; S D Greenberg
Journal:  Am J Clin Pathol       Date:  1989-11       Impact factor: 2.493

6.  Expression of blood group-related antigens and Helix pomatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma.

Authors:  T Kawai; M Suzuki; C Torikata; Y Suzuki
Journal:  Hum Pathol       Date:  1991-02       Impact factor: 3.466

7.  The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.

Authors:  N G Ordóñez
Journal:  Am J Surg Pathol       Date:  1989-04       Impact factor: 6.394

8.  Verification of the histologic diagnosis of malignant mesothelioma in relation to the binding of an antimesothelial cell antibody.

Authors:  A Donna; P G Betta; J S Jones
Journal:  Cancer       Date:  1989-04-01       Impact factor: 6.860

9.  Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung.

Authors:  V Tron; J L Wright; A Churg
Journal:  Arch Pathol Lab Med       Date:  1987-03       Impact factor: 5.534

10.  Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation.

Authors:  K Suzuki; H Kusumoto; Y Deyashiki; J Nishioka; I Maruyama; M Zushi; S Kawahara; G Honda; S Yamamoto; S Horiguchi
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

View more
  11 in total

1.  Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis.

Authors:  Marie-Marthe Philippeaux; Jean-Claude Pache; Sophie Dahoun; Marc Barnet; John-Henri Robert; Jacques Mauël; Anastase Spiliopoulos
Journal:  Histochem Cell Biol       Date:  2004-09-15       Impact factor: 4.304

2.  HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.

Authors:  A D Kennedy; G King; K M Kerr
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

3.  Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies.

Authors:  M W Boehme; Y Deng; U Raeth; A Bierhaus; R Ziegler; W Stremmel; P P Nawroth
Journal:  Immunology       Date:  1996-01       Impact factor: 7.397

Review 4.  Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures.

Authors:  Mallorie Boron; Tiffany Hauzer-Martin; Joseph Keil; Xue-Long Sun
Journal:  TH Open       Date:  2022-07-11

5.  Cellular localization of thrombomodulin in human epithelium and squamous malignancies.

Authors:  D J Lager; E J Callaghan; S F Worth; T J Raife; S R Lentz
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

6.  Expression and localization of thrombomodulin in preneoplastic bronchial lesions and in lung cancer.

Authors:  E Tolnay; T Wiethege; K M Müller
Journal:  Virchows Arch       Date:  1997-03       Impact factor: 4.064

7.  Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.

Authors:  A S Abutaily; B J Addis; W R Roche
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

8.  Effect of Thrombomodulin Alfa on Disseminated Intravascular Coagulation in Patients with Lung Cancer.

Authors:  Kentaro Nakano; Kumiya Sugiyama; Hideyuki Satoh; Hajime Arifuku; Takayoshi Fujimatsu; Naruo Yoshida; Hiroyoshi Watanabe; Shingo Tokita; Tomoshige Wakayama; Masamitsu Tatewaki; Ryosuke Souma; Hiroyuki Masuda; Kenya Koyama; Hirokuni Hirata; Yasutsugu Fukushima
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

9.  In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening.

Authors:  Andrea R Mazzocchi; Shiny A P Rajan; Konstantinos I Votanopoulos; Adam R Hall; Aleksander Skardal
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

10.  Production of endothelin-1 and thrombomodulin by human pancreatic cancer cells.

Authors:  T Oikawa; M Kushuhara; S Ishikawa; J Hitomi; A Kono; T Iwanaga; K Yamaguchi
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.